Yeleswaram Krishnaswamy Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
1
Insider Sells Sum
$85,342.00

Insider Activity of Yeleswaram Krishnaswamy

According to the SEC Form 4 filings, Yeleswaram Krishnaswamy, being in a position of

  1. Chief Development Officer at Rapport Therapeutics, Inc. Common Stock,
    оver the last 12 months, has bought 0 shares, and sold 103969 shares for $4.46M,
    over all time since 2025-12-31, has bought 0 shares, and sold 103969 shares for $4.46M.

Biography of Yeleswaram Krishnaswamy

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$000
Sells
$4,457,67110100

Comparison of Insiders on Amount of Buys and Sells

2026-08-25SaleRapport Therapeutics, Inc. Common Stock
RAPP
Chief Development Officer
37,000
0.0766%
$50.64$1.87M-35.47%
2026-08-24SaleRapport Therapeutics, Inc. Common Stock
RAPP
Chief Development Officer
13,160
0.0281%
$50.00$657,978-32.64%
2026-08-19SaleRapport Therapeutics, Inc. Common Stock
RAPP
Chief Development Officer
404
0.0009%
$49.90$20,160-31.53%
2026-04-17SaleRapport Therapeutics, Inc. Common Stock
RAPP
Chief Development Officer
20,225
0.0558%
$39.99$808,844-2.97%
2026-04-14SaleRapport Therapeutics, Inc. Common Stock
RAPP
Chief Development Officer
10,200
0.0286%
$35.08$357,797+6.69%
2026-04-13SaleRapport Therapeutics, Inc. Common Stock
RAPP
Chief Development Officer
9,165
0.0257%
$34.97$320,537+11.2%
2026-04-10SaleRapport Therapeutics, Inc. Common Stock
RAPP
Chief Development Officer
500
0.0014%
$34.98$17,490+12.64%
2026-04-08SaleRapport Therapeutics, Inc. Common Stock
RAPP
Chief Development Officer
360
0.001%
$34.90$12,564+14.07%
2026-03-25SaleRapport Therapeutics, Inc. Common Stock
RAPP
Chief Development Officer
10,115
0.0288%
$29.99$303,355+31.79%
2025-12-31SaleRapport Therapeutics, Inc. Common Stock
RAPP
Chief Development Officer
2,840
0.0078%
$30.05$85,342+15.95%
Total: 10
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.